

COMPLETE LISTING OF CLAIMS

Please amend claim 4, without prejudice or admission, so that the pending claims will be as shown in the following complete listing of all claims ever presented for this application (37 C.F.R. 1.121(c)):

1. (Original) A method of treating patients who have diseases characterized by bone loss comprising the step of administering to said patient an amount of TRANCE/RANK inhibitors effective to inhibit osteoclastogenesis and/or osteoclast function.
2. (Original) The method of claim 1 wherein said TRANCE/RANK inhibitor is a compound having the Formula I wherein:

R₁, and R₂ are, independently, selected from the group consisting of -H, -OCH₃, -CH₂CH₃, -*t*-butyl, 3-carboxy-4-chlorophenylamino, -N-(CH₂CH₂OH)₂, and -O(O)C-Ph;

R₃ is selected from the group consisting of -H, ethyl, -OCH₃, -Cl, Br, F, 3-carboxy-4-chlorophenylamino, -N-(CH₂CH₂OH)₂, -*t*-butyl, and -OC(O)-Ph, and is not limited to attachment at any certain position on the phenyl ring to which it is attached; and

R₄ is selected from the group consisting of -Br, -Cl, and -F.

3. (Original) The method of claim 2 wherein R₃ is attached at either the 1 or 4 position of the 15 phenyl ring.
4. (Currently amended) The method of claim 1 wherein said TRANCE/RANK inhibitor is a compound having the Formula I wherein:

R₁, R₂, and R₃ are -OCH₃, R₃ is attached at the 4 position, R₄ is -Cl;

R₁, and R₂ are methyl, R₃ is ethyl, attached at the 4 position, R₄ is -Cl;

R₁, and R₂ are -OCH₃, R₃ is -Cl, attached at the 2 position, R₄ is -Cl;

R₁, and R₂ are -OCH₃ and R₃ is H, R₄ is -Cl;

R₁, is H, R₂ and R₃ are 3-carboxy-4-chlorophenylamino, and R₃ is attached at the 4 position, R₄ is -Cl;

R₁ and R₂ are -N(CH₂CH₂OH)₂, R₃ is Cl, attached at the 4 position, R₄ is -Cl;

R₁, R₂, and R₃ are *t*-butyl, R₃ is attached at the 4 position, R₄ is -Cl;

R₁, is -OCH₃, R₂ and R₃ are H, R₄ is Cl; or

R, R₂, and R₃ are benzoate, R₃ is attached at the 4 position, R₄ is Br.

5. (Original) The method of claim 1 wherein said TRANCE/RANK inhibitor is selected from the group consisting I-A, I-B, I-C, I-D, I-E, I-F, I-G, I-H and I-I.

6. (Original) The method of claim 1 wherein said TRANCE/RANK inhibitor is a compound having the Formula II wherein:

R₁ is selected from the group consisting of -diphenylchloro methyl, -di(4chlorophenyl)chloro methyl, and 4-(diphenylchloromethyl)phenyl; and R₂, R₃, R₄ are independently selected from the group consisting of -Br, -Cl, and -F.

7. (Original) The method of claim 6 wherein R₂, R₃, R₄ are each -Cl.

8. (Original) The method of claim 1 wherein the TRANCEIRANK inhibitor is selected from the group consisting compounds II-A, II-B, II-C and II-D.
9. (Original) The method of claim 1 wherein said inhibitor is a compound having Formula III wherein:

$R_1 = (NO_2)_2, O(CO)CH_3, OH, O(CO)CH_3,$
 $O(CO)(CH_2)_2COOH, O(CO)CH_2Br, O(CO)CH_2Cl,$
 $O(CO)CH_2N(CH_3)_3, \text{ or } OC_3H_9O; R_2 = CH_2O(NO_2), CHO,$
 $CH_2O(NO_2), CN, CH_3, COOH, CHNOH,$
 $CH_2O(CO)(CH_2)_2COOH, CHN(NH)CONH_2, CHN(NH)C_6H_5,$
 $CHN(CH_2)C_6H_5, CH_2N(CH_2)_2OH, CH_2NC_6H_5, \text{ or}$
 $CH_2N(NH)CSNH_2;$

$R_3 = OH, \text{ or } H;$

$R_4 = CH_3;$

$R_5 = OH;$

$R_6 = C_6H_5O_2, N(NHCO)C_6H_4Cl, N(NHCO)C_6H_4F, COOH, O,$
 $COCH_3, CH(CH_3)(CH_2)_2COOH, CH(CH_3)(CH_2)_2COOCH_3,$
 $O(CO)C_6H_5, \text{ or } OH;$


$R_7 = O(CO)CH_2N(CH_3)_3, \text{ or } O(CO)CH_3;$

$R_8 = OH;$




$R_9 = O, \text{ or } OH; \text{ and } R_{10} = O$

$R_{10} = O.$


10. (Original) The method of claim 1 wherein the inhibitor is selected from the group consisting compounds III-1 to III-31.
11. (Original) The method of claim 1 wherein said inhibitor is a compound having Formula IV wherein:



12. (Original) The method of claim 1 wherein the inhibitor is selected from the group consisting compounds IV-1 and IV-2.
13. (Original) The method of claim 1 wherein said inhibitor is a compound having Formula V wherein:



14. (Original) The method of claim 1 wherein the inhibitor is selected from the group consisting compounds V-1 and V-5
15. (Original) The method of claim 1 wherein said inhibitor is a compound having Formula VI wherein:



$R_3 = O, \text{ or } OH;$

$R_4 = CH_3;$

$R_5 = C_9H_{13}COCH_3, C_9H_{13}(CH_2CH_3)(CH_2OH),$
 $C_9H_{13}(CH_2CH_3)(CH_2COOCH_3), C_9H_{13}(CH_2CH_3)(CH_2$
 $OCO(CH_2)_2COOH), C_9H_{13}(CH_2CH_3)(COOH), \text{ or}$
 $C_8H_7O(CH_3)(C_4H_9OCH_3);$

$R_6 = CH_3;$

$R_7 = O, \text{ or } H;$

$R_8 = CH_3;$

$R_9 = (CH_3)_2; \text{ and}$

$R_{10} = Br.$

16. (Original) The method of claim I wherein the inhibitor is selected from the group consisting compounds VI-1 and VI-11.
17. (Original) The method of claim I wherein the inhibitor is selected from the group consisting compounds VII, VIII IX, X, XI and XII.

Claims 18-43: (Cancelled)

* * * * *